What is PYC Therapeutics?
PYC Therapeutics is a specialized drug-development enterprise focused on the discovery and advancement of RNA therapeutics. The company operates at the intersection of molecular biology and clinical medicine, targeting complex genetic disorders. Its current portfolio includes the VP-001 program for retinitis pigmentosa type 11, currently in Phase 1 clinical trials, and PYC-001, which addresses Autosomal Dominant Optic Atrophy. Furthermore, the company is advancing PYC-002 for Phelan-McDermid Syndrome and PYC-003 for autosomal dominant polycystic kidney disease. Through strategic academic-industry collaborations, such as its partnership with Murdoch University, the company continues to push the boundaries of neurodegenerative and genetic disease research.
How much funding has PYC Therapeutics raised?
PYC Therapeutics has raised a total of $121.6M across 2 funding rounds:
Other Financing Round
$74.6M
Stock/Share Issuance
$47M
Other Financing Round (2024): $74.6M, investors not publicly disclosed
Stock/Share Issuance (2026): $47M, investors not publicly disclosed
Key Investors in PYC Therapeutics
Undisclosed Investor
An institutional entity providing strategic capital to support the advancement of clinical-stage biotechnology programs.
Undisclosed Investor
A venture capital firm specializing in early-stage and growth-stage investments within the life sciences and drug discovery sectors.
Undisclosed Investor
A private equity group focused on long-term value creation through the funding of innovative medical research and therapeutic development.
What's next for PYC Therapeutics?
Looking ahead, the company is poised to transition its lead candidates through critical clinical milestones. The recent capital injection will be instrumental in funding the ongoing Phase 1 trials and supporting the pre-clinical development of its broader pipeline. As the company scales its operations, the focus will remain on validating the safety and efficacy of its RNA delivery technology. Investors and stakeholders are closely monitoring the progress of these programs, as successful clinical outcomes could pave the way for significant commercialization opportunities and long-term value creation in the high-growth RNA therapeutics market.
See full PYC Therapeutics company page
